New LC-MS system delivers accurate and reproducible results for multi-attribute monitoring of biologics. Eliminates analyte-to-metal surface interactions greatly enhancing recovery of hard-to-detect ...

New Peptide MAM (multi-attribute method) workflow for the BioAccord LC-MS System monitors product quality attributes that can affect efficacy and safety of innovator drugs and biosimilars. End-to-end ...

Waters Corporation WAT launched an integrated high-resolution liquid chromatography mass spectrometry (LC-MS) system, namely the Waters BioAccord System with ACQUITY Premier. The BioAccord System ...

Earlier in 2019, Waters Corporation announced their BioAccord LC-MS System for biopharmaceutical analysis. We spoke with John Gebler, PhD, Director of Strategic Business Development at Waters ...

The system was designed to enhance productivity, positioning the user to acquire and process data with a purpose-built LC-MS platform SANTA CLARA, Calif., Jan. 8, 2020 /PRNewswire/ -- Based on its ...

Waters WAT continues to gain steam in the biopharma industry on the back of its strength across liquid chromatography (LC) and mass spectrometry (MS) analytical techniques. This is evident from its ...

New LC-MS system delivers accurate and reproducible results for multi-attribute monitoring of biologics. Eliminates analyte-to-metal surface interactions greatly enhancing recovery of hard-to-detect ...

Earlier in 2019, Waters Corporation announced their BioAccord LC-MS System for biopharmaceutical analysis. The BioAccord System is a self-calibrating, self-optimizing, self-sufficient tool that ...

Waters Corporation (NYSE:WAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with ...

The system was designed to enhance productivity, positioning the user to acquire and process data with a purpose-built LC-MS platform "The BioAccord LC-MS System was designed to optimize performance ...